anyon show engag
detail review announc acquisit esrx introduc
full pf model lower pt assum deal
closur let us know would like copi pf model turn also
updat view esrx lower ep account modest buy-back
well less sell season traction deal distract vs share gain market
leader also lower pt factor deal close
gross spread note stand-alone valu san deal ci move
esrx
call premis acquir pbm strateg merit investor
struggl time transact pre cliff well long-
term margin profil acquir busi ultim posit deal
must believ esrx margin stay desir level target
market lead pbm seem like clear risk given secular
pbm headwind increas govern scrutini addit achiev ci
target revenu compound-annual-growth-rate requir combo help acceler growth
health plan side also uncertain competit environ
other also promot integr pharmacy-med model struggl
see sustain upward momentum share despit signific sell-off
transact progress toward closur overhang stock could last
quit time given possibl drawn regulatori approv process
time prove esrx run rate earn power follow antm departur howev
given broadli neg feedback investor widen deal spread
esrx market suggest path forward may come
question govern approv merger less certain
given challeng natur altern path albeit imposs
reiter rate equiti
ci valuat lower ci price target upsid base
dcf combin entiti includ cash flow exit
margin eros time repres blend price-to-earnings new pro forma
ep estim earn split nearli legaci ci lower
growth/high margin risk esrx would valu ci stand-alone basi
stand-alone ep estim assum share repo continu instead
lower estim reflect suspens buyback look
model low end manag ep target achiev
core esrx oper margin eros vs current ex off-set
target synergi debt paydown eventu resumpt buyback
strong cash flow gener risk margin compress remain
pf model estim accret
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
valuat methodolog base mix discount cash flow analysi rel valuat multipl
risk valuat includ regulatori risk overal market risk well unforeseen event relat individu cover
compani broader sector includ new competit product technolog
sensit lt valu pbm margin profil esrx incom primarili come
mail order pharmaci secularli challeng specialti pharmaci
increasingli competit like see gross margin degrad two
larg pbm competitor describ target pbm margin seem
esrx current core ebit margin near may unsustain see transact
turn dilut esrx ex-antm oper margin synergi erod
see sensit analysi also uncertainti surround esrx
core remain earn post-antm difficult know diseconomi scale
exist possibl true cost alloc busi could vari
somewhat report answer wont come
busi roll
competit posit fulli improv combin entiti still lack strong
hold higher-growth govern busi line face competitor along
vertic integr deliveri asset strateg valu combin pbm
asset make sens clear trend less clear competit edg
drive market share gain health plan side busi achiev pro forma lt
revenu growth target specialti drug major driver overal medic cost
inflat manag spend crucial compon complet answer
transit value-bas care
evercor isi health facil manag cigna summari incom statement million except per share datafisc year endingdecemb supplement disabl life esrx revenu ex servic fee invest medic medic supplement benefit disabl life benefit benefit benefit supplement loss disabl life loss supplement disabl life sg ex expens ex industri revenu invest oper expens order pharmaci revenu ex supplement disabl life ebit ex intang interest debt less stand-alone debt interest tax expens tax tax incom attribut ep ex intang net incom ex ep ex share repurchas weight averag forma issuanc forma share
express script stat million except per share data fy end decemb growth revenu margin growth revenu ep share net incom price-to-earnings premium/discount isi healthcar technolog distribut march
articl articl
time dissemin march et
analyst michael newshel ross muken elizabeth anderson matthew nicolai suzi yoon primarili respons prepar
research report attest follow view opinion render research report reflect person view
subject compani issuer part research analyst compens directli relat specif
recommend view research report
report approv and/or distribut evercor group llc evercor group licens broker-deal regul
industri regulatori author finra intern strategi invest group uk limit isi uk authoris regul
unit kingdom financi conduct author institut sale trade research busi evercor group isi
uk collect oper global market brand name evercor isi evercor isi evercor group isi uk subsidiari
evercor partner inc evercor partner trademark logo servic mark shown report regist trademark
analyst associ respons prepar report receiv compens base variou factor includ evercor partner
total revenu portion gener affili invest bank transact evercor isi seek updat research
appropri variou regul may prevent happen certain instanc asid certain industri report publish
period basi larg major report publish irregular interv appropri analyst judgment
evercor isi gener prohibit analyst associ member household maintain financi interest secur
compani analyst area coverag except polici requir specif approv member complianc
depart ownership subject complianc applic regul disclosur evercor isi also prohibit analyst associ
member household serv offic director advisori board member employe compani analyst
report may includ tactic call describ near-term event catalyst affect subject compani market overal
expect short-term price impact equiti share subject compani tactic call separ analyst
long-term recommend outperform under-perform reflect stock forward expect return formal rate
may differ target price recommend reflect analyst long-term view
applic current disclosur regard subject compani cover report avail offic evercor isi
obtain write evercor group llc attn complianc fifth avenu floor new york ny
evercor partner affili respect director offic member employe may interest
qualifi hold issuer mention report evercor partner affili may busi relationship
compani mention report
addit inform secur financi instrument mention report avail upon request
evercor isi recommend base stock total forecast return next month total forecast return equal
expect percentag price return plu gross dividend yield divid stock coverag three primari rate categori
outperform total forecast return expect greater expect total return analyst coverag univers
total forecast return expect line expect total return analyst univers
under-perform total forecast return expect less expect total return analyst univers
coverag suspend rate target price remov pursuant evercor isi polici evercor act advisori
capac merger strateg transact involv compani certain circumst
rate suspend evercor isi suspend rate target price stock suffici fundament basi
determin legal regulatori polici constraint around publish rate target price previou rate target price
longer effect compani reli upon
prior octob coverag suspend rate suspend categori includ categori suspend
finra requir member use rate system term buy hold/neutr sell equat
rate categori purpos evercor isi rate distribut outperform
under-perform rate equat buy hold sell respect
prior march evercor isi recommend base stock total forecast return next month
buy total forecast return expect greater
hold total forecast return expect greater equal less equal
sell total forecast return expect less
octob evercor partner acquir intern strategi invest group llc isi group isi uk acquisit
transfer evercor group research sale trade busi isi group decemb combin research sale
trade busi transfer back evercor group intern reorgan sinc acquisit combin research sale
trade busi oper global market brand name evercor isi
isi group isi uk
prior octob rate system isi group llc isi uk base risk adjust total return
buy return
neutral return
cautiou return
disclosur purpos isi group isi uk rate view follow strong buy buy equat buy neutral equat hold
